Securian Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.08M Hold
6,899
0.12% 111
2025
Q4
$3.13M Sell
6,899
-5,417
-44% -$2.33M 0.12% 114
2025
Q3
$4.82M Sell
12,316
-1,126
-8% -$471K 0.13% 123
2025
Q2
$5.98M Sell
13,442
-156
-1% -$71.9K 0.17% 107
2025
Q1
$6.59M Sell
13,598
-211
-2% -$98.3K 0.2% 98
2024
Q4
$5.56M Sell
13,809
-435
-3% -$202K 0.16% 107
2024
Q3
$6.62M Sell
14,244
-551
-4% -$265K 0.19% 91
2024
Q2
$6.93M Sell
14,795
-384
-3% -$167K 0.2% 92
2024
Q1
$6.34M Sell
15,179
-1,145
-7% -$484K 0.19% 100
2023
Q4
$6.64M Sell
16,324
-2,177
-12% -$804K 0.19% 94
2023
Q3
$6.43M Sell
18,501
-3,131
-14% -$1.1M 0.19% 100
2023
Q2
$7.61M Sell
21,632
-270
-1% -$91K 0.2% 101
2023
Q1
$6.9M Buy
21,902
+168
+0.8% +$50.4K 0.18% 109
2022
Q4
$6.28M Buy
21,734
+216
+1% +$65.8K 0.18% 117
2022
Q3
$6.23M Buy
21,518
+228
+1% +$65.6K 0.19% 100
2022
Q2
$6M Hold
21,290
0.14% 152
2022
Q1
$5.56M Sell
21,290
-233
-1% -$55.3K 0.11% 186
2021
Q4
$4.73M Sell
21,523
-891
-4% -$173K 0.09% 218
2021
Q3
$4.07M Sell
22,414
-205
-0.9% -$40K 0.08% 224
2021
Q2
$4.56M Sell
22,619
-267
-1% -$55.8K 0.09% 212
2021
Q1
$4.92M Sell
22,886
-782
-3% -$172K 0.11% 196
2020
Q4
$5.59M Sell
23,668
-414
-2% -$95K 0.13% 179
2020
Q3
$6.55M Sell
24,082
-412
-2% -$114K 0.16% 139
2020
Q2
$7.11M Sell
24,494
-1,167
-5% -$316K 0.18% 128
2020
Q1
$6.11M Sell
25,661
-409
-2% -$93.8K 0.17% 136
2019
Q4
$5.71M Sell
26,070
-812
-3% -$164K 0.13% 178
2019
Q3
$4.55M Sell
26,882
-140
-0.5% -$24.8K 0.1% 208
2019
Q2
$4.96M Buy
27,022
+336
+1% +$58.7K 0.11% 182
2019
Q1
$4.91M Buy
26,686
+164
+0.6% +$30.3K 0.12% 179
2018
Q4
$4.39M Buy
26,522
+173
+0.7% +$30K 0.12% 176
2018
Q3
$5.08M Buy
26,349
+65
+0.2% +$11.6K 0.12% 176
2018
Q2
$4.47M Buy
26,284
+164
+0.6% +$25.4K 0.11% 196
2018
Q1
$4.26M Buy
26,120
+200
+0.8% +$32.7K 0.11% 195
2017
Q4
$3.88M Buy
25,920
+365
+1% +$54K 0.1% 214
2017
Q3
$3.88M Buy
25,555
+369
+1% +$55.5K 0.1% 208
2017
Q2
$3.25M Buy
25,186
+257
+1% +$30.9K 0.09% 236
2017
Q1
$2.73M Buy
24,929
+44
+0.2% +$3.87K 0.07% 261
2016
Q4
$1.83M Buy
24,885
+352
+1% +$28.6K 0.05% 342
2016
Q3
$2.14M Buy
24,533
+357
+1% +$33.7K 0.06% 304
2016
Q2
$2.08M Buy
24,176
+214
+0.9% +$18.5K 0.06% 298
2016
Q1
$1.91M Buy
23,962
+291
+1% +$26.3K 0.05% 318
2015
Q4
$2.98M Buy
23,671
+627
+3% +$75.7K 0.09% 221
2015
Q3
$2.4M Sell
23,044
-92
-0.4% -$11.8K 0.08% 238
2015
Q2
$2.86M Buy
23,136
+480
+2% +$60.5K 0.09% 232
2015
Q1
$2.67M Buy
22,656
+819
+4% +$98.1K 0.08% 250
2014
Q4
$2.59M Buy
21,837
+855
+4% +$96.3K 0.08% 239
2014
Q3
$2.36M Buy
20,982
+9
+0% +$857 0.08% 249
2014
Q2
$1.99M Buy
20,973
+58
+0.3% +$4.07K 0.07% 274
2014
Q1
$1.48M Buy
20,915
+174
+0.8% +$13.8K 0.05% 314
2013
Q4
$1.54M Buy
20,741
+131
+0.6% +$9.12K 0.06% 307
2013
Q3
$1.56M Sell
20,610
-12,565
-38% -$1,000K 0.06% 290
2013
Q2
$2.65M Buy
+33,175
New +$2.44M 0.11% 198

Other funds holding VRTX

Securian Asset Management's VRTX Position: Q1 2026 in Review

Securian Asset Management held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 6,899 shares worth $3.08M. The position accounts for 0.12% of the portfolio, ranked #111.

Securian Asset Management first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $7.61M in Q2 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Securian Asset Management held 6,899 shares of Vertex Pharmaceuticals worth $3.08M as of Q1 2026.
  • Securian Asset Management left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
  • Vertex Pharmaceuticals made up 0.12% of Securian Asset Management's portfolio in Q1 2026, its #111 holding.
  • Securian Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Securian Asset Management's Vertex Pharmaceuticals position peaked at $7.61M in Q2 2023.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Securian Asset Management's 13F filing for Q1 2026, filed 1 May 2026.